Williams Kherkher is representing a Pennsylvania woman who is now the third person to file suit against the Olympus manufacturing company responsible for the PKS PlasmaSORD Bipolar Morcellator after the machine was found to have caused the spread of uterine cancer. The complaint, along with the two existing complaints, claims that Olympus either knew or should have known that the power morcellator could potentially cause the spread of undetected cancer cells during gynecological surgery.
The device was approved under a 501(k) by the U.S. Food and Drug Administration several decades ago, as it was “substantially equivalent” to previously approved technology and therefore allowed to bypass testing. The morcellator uses cutting jaws to remove tissue laparoscopically, and has caused damage by cutting through uterine fibroids that contained cancerous cells, allowing them to propagate throughout the abdomen and pelvis. The consequences are an increased rate of cancerous growth and a worsened prognosis.
The FDA eventually recognized the risks associated with these devices and published a safety warning regarding the potential danger of power morcellator use during hysterectomies and myomectomies. In response to numerous lawsuits, Johnson and Johnson voluntarily recalled all of their power morcellators in 2014. Other makers, however, have threatened to pursue legal action against individuals or parties who denounce their product.
In the U.S., ovarian cancer is considered the fifth most fatal cancer among women, and the most fatal cancer caused by the female reproductive system. According to the American Cancer Society (ACS), a woman’s risk of developing this serious medical condition during her lifetime is approximately 1 in 75.
In 2015, ACS estimated that there will be about 21,290 new cases of ovarian cancer. Tragically, ACS also estimated that approximately 14,180 women will die from the disease. As such, it is important for women, especially those who are over the age of 60 and those who are experiencing signs and symptoms of ovarian cancer, to get themselves tested for accurate diagnosis and prompt treatment.
Unfortunately, some studies suggest that women who have undergone laparoscopic procedures involving a power morcellator are at higher risk of ovarian cancer. To know more about holding the manufacturers of this medical device accountable for these damages, speak with our team of power morcellator attorneys at Williams Kherkher by calling (888) 220-0640 today.
On September 4, the U.S. Government Accountability Office (GAO) announced the launch of an investigation regarding the widespread use of power morcellators and their reputation of spreading cancerous tissues to the inner lining of the uterus. The investigation was granted after Congress members requested to investigate the U.S. Food and Drug Administration’s (FDA) approval of these devices.
The power morcellator is a medical device used in minimally invasive surgeries that breaks tissue masses into fragments. Last November, the FDA announced the health risks posed by the use of these devices, recommending that the devices should come with a warning about the possible spread of undetected uterine cancer.
If you believe that the use of this device has, in any way, negatively impacted your health, we have a team of power morcellator lawyers at Williams Kherkher who might be able to help you take legal action against the device’s manufacturer. Call us today at (800) 220-9341 to learn more.
Twelve lawmakers have asked a government watchdog agency to inquire further as to why the U.S. Food and Drug Administration (FDA) took a long time to warn about power morcellators‘ risk of spreading undetected uterine cancer, Medscape reported on Tuesday, August 11.
In a letter addressed to the U.S. Government Accountability Office (GAO), the members of Congress requested a study about the FDA’s delayed response over the medical device’s cancer risk. Lawmakers also asked the GAO to investigate whether the FDA’s current process of approving medical devices was enough to detect the dangers posed by the device.
In April 2014, the FDA advised surgeons to stop using power morcellators for uterine fibroid removal after learning that 1 in 350 women with benign uterine masses have undetected uterine cancer.
If your health has been compromised after undergoing a laparoscopic procedure involving a power morcellator, our team of power morcellator attorneys at Williams Kherkher might be able to help you secure the compensation you believe you deserve from the device manufacturer involved. Call us at (800) 220-9341 and tell us more about your situation.
Patients whose endometrial cancer has been diagnosed and treated early on have a better chance of survival and cure. In fact, diagnosing and treating earlier stages of endometrial cancer (stage 0 to stage 2) provide a 5-year survival rate of 69% to 90%. So, at the early stages at least, there are a majority of good outcomes for endometrial cancer patients.
One of the most effective treatment options for endometrial cancer is chemotherapy. Chemotherapy involves the use of a combination of drugs to fight against cancer. Because these cancer-fighting drugs reach throughout the body, chemotherapy is an effective treatment for endometrial cancer that has already spread beyond the uterus and the pelvic area.
Hysterectomies utilizing power morcellators have been found to increase the risk of spreading undetected uterine cancer. If you have been harmed by this device, you might be eligible to file a claim against the manufacturer of this product. To learn more about seeking compensation, consult with our power morcellator legal team at Williams Kherkher by calling (888) 220-0640 today.
Uterine cancer is considered among the deadliest types of cancer affecting women. In fact, the American Cancer Society predicts that this year, about 10,170 women will die from uterine cancer complications. The agency also said approximately 54,870 women will be diagnosed with the disease.
One of the most common endometrial cancer treatments is radiation therapy. Radiation therapy involves the use of radiation to kill cancer cells and can be performed using a machine outside the body (external beam radiation), or a radiation-filled device placed inside the body (brachytherapy). However, people undergoing radiation therapy for uterine cancer may experience some side-effects, such as rectal bleeding, bladder irritation, incontinence, and sexual problems.
Some studies showed that the risk of uterine cancer is higher among women who have undergone laparoscopic procedure involving a power morcellator. If this device has caused you harm, you might be eligible to seek compensation from the manufacturer involved. Speak with our team at Williams Kherkher by calling (888) 220-0640 today to learn more about filing a lawsuit.
Earlier this month, lawyers of plaintiffs who sued J&J over its power morcellator filed a request to consolidate similar suits in Multidistrict Litigation (MDL). MDL is a legal procedure that combines comparable lawsuits filed by different parties. This is different from class action, which involves a single lawsuit collectively filed by representatives of a larger group of complainants.
Both MDL and class action suits are used by the U.S. courts to manage mass torts. These tools make pre-trial procedures, including the discovery of evidence, more consolidated, convenient, and expeditious. However, because a class action involves only one lawsuit, all class member claimants are bounded by the same settlement and would receive substantially identical compensations. On the other hand, because MDLs are considered separate cases, claimants can be awarded recovery amounts based on the damages they individually claimed.
If you have been harmed by a power morcellator, our team of product liability attorneys at Williams Kherkher may help you file a claim against the manufacturer involved. Call us at (888) 220-0640 today to learn more.
Researchers at the University of Melbourne found that women with Lynch syndrome have a lower risk of uterine cancer if they are taking hormonal contraceptives or have been pregnant before, Health Canal reported on July 7.
The study, which involved 1,128 women with a gene mutation that causes Lynch syndrome, found that women who had one child were 60% less likely to have uterine cancer compared to those who had none. The risk became even lower for women with more than one child. On the other hand, women who took hormonal contraceptives for at least a year decreased their risk of uterine cancer by 50%.
Lynch syndrome is a genetic disease that increases a woman’s risk of certain types of cancer, including uterine cancer. One in 1,000 women has a Lynch syndrome-causing gene mutation.
Apart from Lynch syndrome, the use of a power morcellator during hysterectomies also increases a woman’s risk of uterine cancer. Speak with an attorney at Williams Kherkher by calling (888) 220-0640 to learn more about how to hold the maker of this dangerous medical device accountable for the harm it has caused you.
Lawyers of plaintiffs that filed cases against Johnson & Johnson over allegations that its power morcellator device has caused them uterine cancer are seeking to consolidate similar suits across the country in Multidistrict Litigation (MDL), Reuters reported on June 22.
Attorneys of six complainants filed a request to the U.S. Judicial Panel on Multidistrict Litigation to consolidate at least 22 claims pending in 16 different states across the country. Plaintiff lawyers hope that the cases will go before U.S. District Judge Kathryn Vratil in Kansas. During an MDL, affected parties can choose representative cases in bellwether hearings, which could significantly influence the outcomes of the lawsuits.
If you have been harmed as the result of a medical procedure that utilized a power morcellator, you may seek financial compensation from the medical device manufacturer for your expenses and suffering. The team at Williams Kherkher may help you in your pursuit of justice and compensation. Call us at (888) 220-0640 for a free case assessment today.
A new study found that women who have undergone tubal ligation (TL) at a younger age before developing endometrial cancer later in life have a better endometrial cancer prognosis, Medpage Today published on June 20.
The study involved 4,489 women, 27.6% of whom underwent TL at an average of 32 years old. It found that tubal ligated women were less likely to be diagnosed with stage III or IV uterine cancer. Researchers believe that blocking the fallopian tubes through ligation would interrupt the tubal passage of the cancer cells from the uterus. This would halt metastasis of aggressive cancers and would result in an improved prognosis.
The endometrium, or the inside lining of the uterus, is considered among the potential sources of aggressive cancer cells in a woman’s reproductive system.
Women who have undergone a hysterectomy involving a power morcellator are at an increased risk of uterine cancer. To learn if your situation allows you to seek compensation from the medical device manufacturer, speak with an attorney at Williams Kherkher by calling (888) 220-0640 today.
« Previous 1 2 3 4 5 6 7 Next »